Ryan Fischer's Blog – April 2015 Archive (2)

BioMarin Update

BioMarin has provided the following update on redosing of drisapersen for a new clinical trial. Ambulation will not be an inclusion or exclusion criterion for enrollment, but boys will need to have been previously dosed as part of a clinical trial.

BioMarin Update on Duchenne Muscular Dystrophy…


Added by Ryan Fischer on April 14, 2015 at 9:00am — No Comments

Sarepta Update

Earlier this month Sarepta announced a change in leadership, with CMO Ed Kaye taking over as interim CEO.

Following that announcement the team at Sarepta organized a call with Duchenne patient organizations and foundations to update them…


Added by Ryan Fischer on April 13, 2015 at 11:00am — No Comments

Need help using this community site? Visit Ning's Help Page.



© 2021   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service